• MaxCyte to Participate in Upcoming Investor Conferences

    ソース: Nasdaq GlobeNewswire / 02 11 2022 07:05:00   America/Chicago

    ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Company management will participate in the following investor conferences:

    • Stifel Healthcare Conference
      Wednesday, November 16th at 3:00 p.m. Eastern Time
    • Stephens Annual Investment Conference
      Thursday, November 17th at 10:00 a.m. Eastern Time

    Live and archived webcasts of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

    About MaxCyte

    MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

    MaxCyte Contacts:

    US IR Adviser
    Gilmartin Group
    David Deuchler, CFA
    +1 415-937-5400
    jr@maxcyte.com

    US Media Relations
    Seismic Collaborative, A Spectrum Science Company
    Valerie Enes
    +1 408-497-8568
    valerie@teamseismic.com

    Nominated Adviser and Joint Corporate Broker
    Panmure Gordon
    Emma Earl / Freddy Crossley
    Corporate Broking
    Rupert Dearden
    +44 (0)20 7886 2500

    UK IR Adviser
    Consilium Strategic Communications
    Mary-Jane Elliott / Chris Welsh
    +44 (0)203 709 5700
    maxcyte@consilium-comms.com


    Primary Logo

シェアする